KRAS and non-small cell lung carcinoma: Additional therapeutic strategies for mutant KRAS NSCLC such as reovirus type 3 [139], docetaxel nanoparticles (NCT02283320) or abemaciclib (a cell cycle inhibitor selective for the cyclin-dependent kinases CDK4 and CDK6) [140] are currently under development.